# Obeticholic Acid for Prevention in Barrett's Esophagus

> **NCT04939051** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (estimated)

## Conditions studied

- Barrett Esophagus
- Esophageal Adenocarcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Esophageal Biopsy
- **PROCEDURE:** Esophagogastroduodenoscopy
- **PROCEDURE:** Liver Ultrasonographic Elastography
- **BIOLOGICAL:** Obeticholic Acid
- **DRUG:** Placebo Administration
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04939051
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-03
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939051, "Obeticholic Acid for Prevention in Barrett's Esophagus". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT04939051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*